DiaMedica Therapeutics Inc
NASDAQ:DMAC
DiaMedica Therapeutics Inc
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
Cash Position: DiaMedica ended Q3 2025 with $55.3 million in cash, boosted by a July private placement and enough to fund operations into the second half of 2027.
Preeclampsia Progress: Positive interim Phase 2 results for DM199 in preeclampsia showed significant, dose-dependent reductions in blood pressure and improved placental blood flow.
US Trial Plans: The company completed a productive pre-IND FDA meeting and expects to start a US Phase 2 preeclampsia trial focused on early onset patients.
Stroke Trial Update: Enrollment in the Phase 2b/3 ReMEDy2 stroke trial is progressing slower than expected due to changes in patient referral patterns, with interim analysis now planned for the second half of 2026.
Operating Expenses: R&D and administrative expenses increased year-over-year, mainly due to expanded clinical activities and team growth.
Net Loss: Net loss increased to $8.6 million for Q3 and $24.0 million for the first nine months of 2025, higher than the prior year.
